Funds have been accumulating for the past 21 weeks. The new holders will not sell until 220. More stable holders now. It means that there are very few shares around to trade. Tp 220
The toxic nature of gild's drug will force patients to stop taking it quickly.
who will win? Whales of course.
Pbyi has a potential of much smaller revenue and is worth more than pcyc? Hence pcyc is catching up since the main competition concerns is now a non-issue. Target price is now 220.
This is a million dollar question for all investors. The answer is no. It has been accumulated for the past 21 weeks. This move is to 190, but will not be in a straight line, I warn you.
I get #$%$ off only if I get the trend wrong. Made 30% on the last leg up. Could have been more, but this pos runs according to the fib numbers and Gann squares. You need to execute right on time and resistance to make money. No hesitance. It is a decent trading vehicle if you study it hard instead of ranting. This pos has a shetty personality.
Stargatefan, you have so much emotion toward this pos. it is a trading vehicle. It can be a good long or a good short. The crooks make you money if you short. No worry.
I would stay away from DATA to avoid SNDK earning disaster.
lots of buys after the new Quarter began. Hold onto your shares and call options.
I just want to remind anyone holding the shares not to forget the actual sales and earning for the next 2-3 years. The sales numbers are validating quickly now and the technicals on the chart are telling you now.
adding off label use for large cell follicular lymphoma will lead to even higher numbers.
see if anyone can come up with best estimate which will translate to stock price performance. For 2015 my estimate is at least 1000-1100 millions for US and 500-550 millions for EU. For 2016 1700-1850 millions for US and 1000-1100 millions for EU. This will be 1600 millions next year for 2015 and 2900 millions for 2016 for US and EU together. PCYC will get half of all that. 1.5 billions divide by 3 for the actual net and divide by 75 million shares, you get 6.67 earning per share conservatively. PE of 30 tranlates to 200 dollars per share. So figure, PCYC should have PS of 15 to 1 next year and 12 to one 2016. That translates to MKT CAP 12 billions for the coming year (price is starting to validating it now to the next 2-3 months) and 17-18 billions for the year afterward. This only includes US and EU without the rest of the world and Immunologic indications for Ibrutinib. This is a double in the next 2-3 months and a triple next year. Add some explosive stimulus from immunologic and adjuvant Multiple Myeloma indications to the market cap you will come up with a quadruple from now. However, JNJ will buy this out before it all pan out at 180 to 190. But add the gamblers to the mix, you have a super high volitility to the ride. Please tighten your seatbelt and hold onto your shares. Put all the fundamentals aside Technicals which I trust 99% of the time are turning to the explosive side now.
You are treating this whole thing as gambling. You should base your investing on math and geometry of exact science to improve your chance of winning trade.
yep, but don't expect a smooth ride. next week to the end of the month the general market will have volitility, especially moving into august which is expected to be a negative month.